Abstract Neuroinflammation is a prominent feature in Alzheimer's disease (AD) and activation of the brain's innate immune system, particularly microglia, has been postulated to both retard and accelerate AD progression. Recent studies indicate that the G protein-coupled P2Y 2 nucleotide receptor (P2Y 2 R) is an important regulator of innate immunity by assisting in the recruitment of monocytes to injured tissue, neutrophils to bacterial infections and eosinophils to allergeninfected lungs. In this study, we investigated the role of the P2Y 2 R in progression of an AD-like phenotype in the TgCRND8 mouse model that expresses Swedish and Indiana mutations in amyloid precursor protein (APP). Our results indicate that P2Y 2 R expression is upregulated in TgCRND8 mouse brain within 10 weeks of age and then decreases after 25 weeks of age, as compared to littermate controls expressing low levels of the P2Y 2 R. TgCRND8 mice with homozygous P2Y 2 R deletion survive less than 5 weeks, whereas mice with heterozygous P2Y 2 R deletion survive for 12 weeks, a time point when TgCRND8 mice are fully viable. Heterozygous P2Y 2 R deletion in TgCRND8 mice increased β-amyloid (Aβ) plaque load and soluble Aβ 1-42 levels in the cerebral cortex and hippocampus, decreased the expression of the microglial marker CD11b in these brain regions and caused neurological deficits within 10 weeks of age, as compared to age-matched TgCRND8 mice. These findings suggest that the P2Y 2 R is important for the recruitment and activation of microglial cells in the TgCRND8 mouse brain and that the P2Y 2 R may regulate neuroprotective mechanisms through microglia-mediated clearance of Aβ that when lost can accelerate the onset of an AD-like phenotype in the TgCRND8 mouse.
Introduction
Neuroinflammation is manifested in Alzheimer's disease (AD), yet it remains unclear whether inflammation is a primary cause of disease progression or a protective response [1, 2] . During early stages of neuroinflammation, activated microglia secrete cytokines, chemokines and growth factors that induce neuroprotective responses [3, 4] . Previous studies have shown that modulation of inflammation in animal models of AD can affect disease progression [5] [6] [7] ; however, clinical trials using anti-inflammatory drugs in AD have been inconclusive [2] . Therefore, unraveling the complex neuroinflammatory mechanisms associated with AD is necessary for development of novel AD therapies.
Extracellular nucleotides (e.g., ATP, ADP, UTP) are released from many cell types in response to both physiological and pathological stimuli, which activate a family of cell-surface nucleotide receptors consisting of seven ligand-gated ion channels (i.e., P2XR1-7) and eight G protein-coupled receptors (i.e., P2YR 1, 2, 4, 6, [11] [12] [13] [14] [8, 9] to regulate a range of physiological responses [10] [11] [12] , including neuroinflammation [13] . In particular, the G q protein-coupled P2Y 2 receptor (P2Y 2 R) that is activated equipotently by ATP or UTP [14] [15] [16] has been identified as a modulator of neuroinflammatory processes, including those relevant to AD pathology [17] [18] [19] . Upregulation of P2Y 2 Rs under inflammatory conditions occurs in a variety of tissues and cells [20] [21] [22] [23] , including brain cells [24, 25] , whereupon activation by ATP or UTP stimulates growth factor receptors, integrins and cytoskeletal proteins via unique structural motifs in the P2Y 2 R that enable access to signaling pathways beyond the G q protein [26] . In rat primary cortical neurons, P2Y 2 Rs are upregulated following treatment with interleukin-1β (IL-1β) [24] , a cytokine shown to be elevated in AD patients [27, 28] . Subsequent P2Y 2 R activation stimulates nonamyloidogenic processing of amyloid precursor protein (APP) [24] . In mouse primary microglia, Aβ 1-42 treatment induces P2Y 2 R upregulation that promotes microglial cell migration, and Aβ 1-42 uptake and degradation [25] . P2Y 2 R activation has been shown to inhibit trauma-induced death of astrocytic cells [29] , suggesting that neuroprotective responses occur following activation of microglial, astrocytic and neuronal P2Y 2 Rs. Recent studies with post-mortem human AD brains have shown a decreased expression of P2Y 2 Rs, as compared to non-AD controls [30] . However, the role of P2Y 2 R-mediated neuroprotection in AD remains unclear.
In this study, we assessed the effect of P2Y 2 R deletion in TgCRND8 mice, a well-studied AD mouse model that expresses the Swedish and Indiana mutant of APP (KM670/ 671NL+V717F) [31] . We found that homozygous or heterozygous deletion of the P2Y 2 R significantly decreases longevity of the TgCRND8 mouse. Additionally, the heterozygous P2Y 2 R deletion was sufficient to significantly increase soluble Aβ 1-42 levels and appearance of neurological deficits, as well as decrease the expression of the microglial cell marker CD11b in the brain, as compared to TgCRND8 mice with a full complement of the P2Y 2 R. Taken together, our data suggest a neuroprotective function for the P2Y 2 R in the TgCRND8 mouse that may represent a novel therapeutic target for the treatment of AD, as well as other neurodegenerative diseases.
Methods

Reagents
TRIzol reagent, AlexaFluor 488 goat anti-rabbit IgG antibody, Texas Red goat anti-rat IgG antibody, Hoescht 33258 nuclear stain and the anti-human Aβ 1-42 sandwich ELISA kit were obtained from Life Technologies (Grand Island, NY, USA).
All other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.
Mice
All animals were handled using protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Missouri (protocol #6728). Heterozygous TgCRND8 mice (Tg + ), which express human APP containing the Swedish (K670N/M671L) and Indiana (V717F) mutations, were obtained from Dr. David Westaway (University of Toronto) [31] and were maintained on a mixed C3H/C57BL/6 strain background. Non-transgenic littermate (Tg − ) mice on the mixed C3H/C57BL/6 strain background that do not express human APP with Swedish and Indiana mutations were used as negative controls for experiments. P2Y 2 R −/− mice (stock #009132) were purchased from Jackson Laboratories (Bar Harbor, ME) and were maintained on a C57BL/6 strain background. ) homozygous knockout mice. All mice were bred at the Christopher S. Bond Life Sciences Center Animal Facility of the University of Missouri, Columbia, MO. Animals were housed in vented cages with 12 h light/dark cycles and received food and water ad libitum. All mice were genotyped by PCR using appropriate primers, as described previously [31, 32] . Age-matched male and female mice were utilized for all experiments. ) mice were excised and the olfactory bulb and cerebellum were removed. The cortex and hippocampus from one hemisphere were then homogenized in TRIzol Reagent and incubated at room temperature for 5 min. Chloroform (0.2 ml/ml TRIzol) was added and the samples were incubated for 5 min at room temperature. Following centrifugation (12,000×g for 15 min at 4°C), total RNA was isolated from brain samples and purified using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA, USA). cDNA was synthesized from 500 ng purified RNA using the Advantage RT for PCR Kit (Clontech Laboratories, Mountain View, CA, USA). TaqMan probes for P2Y 2 R, CD11b and 18S endogenous control were obtained from Applied Biosystems (Foster City, CA, USA). The samples were prepared in quadruplicate and subjected to RT-PCR on an Applied Biosystems 7500 Real-Time PCR machine. After computing the relative amounts of the target gene, the data were normalized to 18S for each sample and analyzed using Applied Biosystems software.
Immunohistochemistry and Immunofluorescence Microscopy
Whole mouse brains were excised, placed in 4 % (v/v) paraformaldehyde in PBS for 24 h and sent to IDEXX RADIL (Columbia, MO, USA) where brains were embedded in paraffin and 5-μm coronal sections were prepared from each of the frontal, parietal and occipital lobes and the cerebellum. Slides were then stained with Congo Red and subjected to brightfield and polarized light microscopy. For quantification of amyloid plaques, a blind study was conducted by IDEXX RADIL in which Congo Red stained slides from Tg + and Tg + P2Y 2 R +/− (n = 5) mouse brain were viewed under polarized light and amyloid plaques displaying apple-green birefringence were manually counted. Alternatively, mouse brains were excised, snap frozen in 2-methylbutane chilled in liquid nitrogen and stored at −80°C for further use. Brains were then thawed to −20°C and 10-μm sections were cut using a Leica CM1900 cryostat. Sections were adhered to glass slides and fixed in 4 % (v/v) paraformaldehyde for 20 min at 4°C followed by three 5-min washes in PBS. Sections were then treated with 0.1 % (v/v) Triton X-100, washed three times in PBS and incubated for 2 h at room temperature in blocking buffer (5 % (v/v) goat serum and 0.3 M glycine in PBS). Sections were incubated with rabbit anti-β-amyloid antibody (1:200 dilution in blocking buffer; Cell Signaling Technology, Danvers, MA, USA) for 16 h at 4°C. Following three 5-min washes in PBS, sections were incubated for 1 h at room temperature in blocking buffer containing AlexaFluor 488 goat anti-rabbit IgG antibody diluted 1:1,000 in blocking buffer. Following three washes in PBS, sections were incubated for 5 min at room temperature in Hoechst 33258 nuclear stain diluted 1:5,000 in PBS. Slides were washed three times in PBS, mounted and fluorescence was visualized using a Nikon Ti-E inverted microscope equipped with appropriate filters. Measurement of plaque size was performed on anti-β-amyloid antibody-stained brain sections by outlining plaques using the area auto-detect tool in the NIS Elements software (Nikon). ) mice (n =8) were excised and the olfactory bulb and cerebellum were removed. The cortex and hippocampus from one hemisphere were then homogenized in reaction buffer BSAT-DPBS comprised of 5 % (w/v) bovine serum albumin, 0.03 % (v/v) Tween-20 and protease inhibitor cocktail (Sigma-Aldrich) in PBS according to the manufacturer's instructions. For measurement of total Aβ 1-42 levels, one aliquot of brain homogenate was extracted with 5 M guanidine-HCl in 50 mM Tris-HCl at pH 8 followed by sonication. For measurement of soluble Aβ 1-42 levels, one aliquot of brain homogenate was extracted with 0.4 % (v/v) diethylamine in 100 mM NaCl, as described [33] . Samples were then diluted 1:50 in cold reaction buffer and centrifuged at 16,000×g for 20 min at 4°C. Quantification of Aβ levels was performed using an anti-human Aβ ) mice were excised and the olfactory bulb and cerebellum were removed. The cortex and hippocampus from one hemisphere were then homogenized in TPER (Tissue Protein Extraction Reagent; Thermo Scientific, Rockford, IL). Samples were centrifuged at 10,000×g for 5 min to pellet cellular debris and supernatants were collected. Samples were normalized for p r ot e i n co n c e n t r a t i o n u s i n g a N an o D r o p 1 0 0 0 spectrophotometer and combined 1:1 with 2× Laemmli buffer (20 mM sodium phosphate, pH 7.0, 20 % (v/v) glycerol, 4 % (w/v) SDS, 0.01 % (w/v) bromophenol blue and 100 mM dithiothreitol). For measurement of soluble APPα (sAPPα) levels, 10 % (w/v) homogenates of brain samples were prepared in buffer (250 mM sucrose, 20 mM Tris, 1 mM EDTA, 1 mM EGTA and protease inhibitor cocktail, according to the manufacturer's instructions, pH 7.4) and extracted with an equal volume of 0.4 % (v/v) diethylamine in 100 mM NaCl. Samples were then centrifuged at 100, 000×g for 1 h at 4°C and supernatants were collected, neutralized with 0.1 volume of 0.5 M Tris (pH 6.8) and combined 4:1 with 5× Laemmli buffer. Western blot analysis was performed, as previously described [24] . Briefly, samples were subjected to 7.5 % (w/v) SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked for 1 h with 5 % (w/v) non-fat dry milk in Tris-buffered saline containing 0.1 % (v/v) Tween-20 (TBST) and incubated overnight at 4°C with 1:1,000 dilution in TBST of mouse anti-human APP antibody clone 6E10 (Covance, Princeton, NJ, USA), mouse anti-human sAPPα antibody clone 2B3 (Immuno-Biological Laboratories, Minneapolis, MN), rabbit anti-mouse ADAM10 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-mouse ADAM17 antibody (Santa Cruz Biotechnology), rabbit anti-mouse BACE1 antibody (Cell Signaling Technology) or rabbit anti-mouse α-tubulin antibody (Cell Signaling Technology). Membranes were washed three times in TBST and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody or goat anti-mouse IgG antibody (1:2,000 dilution in TBST, Santa Cruz Biotechnology) at room temperature for 1 h. Blots were washed three times in TBST and visualized using enhanced chemiluminescent reagent (Thermo Scientific) for 1 min. Protein bands were detected on X-ray film and quantified using a computer-driven scanner and Quantity One software (Bio-Rad, Hercules, CA, USA).
Gait Analysis
Gait parameters were evaluated using the CatWalk 7.1 system from Noldus Information Technology (Leesburg, VA, USA). The CatWalk system objectively measures various parameters of gait including stride length, swing speed, paw contact area and step sequence patterns, among others. All data analyses were performed with a pixel threshold value ≥25 arbitrary units. Tg + and Tg + P2Y 2 R +/− mice were subjected to 3 days of walkway training and testing was performed on day 4 when the animals completed three runs without hesitation.
Statistical Analysis
Quantitative data are presented as the means ± SEM of results from three or more independent experiments. Statistical significance was defined as P <0.05 and was calculated by two-tailed t-test or ANOVA where indicated, using GraphPad Prism software. Statistical differences between Kaplan-Meier survival curves were determined by Mantel-Cox test where significance was defined as P <0.05.
Results
P2Y 2 Receptor Upregulation in the Brain of TgCRND8 Mice
Previous studies have demonstrated upregulation of the P2Y 2 R under various inflammatory conditions [20, 22, 23, 34] . Further studies from our laboratory indicate that IL-1β or Aβ 1-42 induces P2Y 2 R upregulation in primary cortical neurons and microglia [24, 25] . Since increased levels of IL-1β and Aβ are observed in the brains of AD mouse models [31] and AD patients [27] , we investigated the expression levels of P2Y 2 R mRNA in the brains of TgCRND8 (Tg Results show that by 10 weeks of age, P2Y 2 R mRNA is significantly upregulated in TgCRND8 mouse brain, as compared to Tg − littermate controls (Fig. 1) . Upregulation of the P2Y 2 R is sustained through 25 weeks of age, but decreases by 48 weeks of age (Fig. 1 ). These data indicate that the P2Y 2 R is upregulated in the brains of the TgCRND8 mouse model of AD at times when neuroinflammation is manifested, but not at a time point that corresponds to advanced stage of AD pathology [35] .
P2Y 2 R Knockout in TgCRND8 Mice Increases Mortality
To investigate the role of the P2Y 2 R in an AD mouse model, TgCRND8 mice were crossed with P2Y 2 R −/− mice.
Surprisingly, homo-or heterozygous knockout of the P2Y 2 R significantly increases mortality in the TgCRND8 mice. As shown in Fig. 2a , Kaplan-Meier survival curves were generated for each of the following genotypes: TgCRND8 (n =25; Tg
P2Y 2 R −/− (n =24) and TgCRND8 × C57BL/6 (n =27) mice. ) and age-matched non-transgenic littermate control (Tg − ) mice were harvested at the indicated time points and subjected to RT-PCR analysis using specific primers for the P2Y 2 R, as described in Methods. Data are presented as means ± SEM (n =4 at 8, 13 and 20 weeks, n =6 at 10 and 16 weeks and n =3 at 25 and 48 weeks) of the fold increase in P2Y 2 R mRNA expression for Tg + over Tg − control mice, where *P <0.05 and **P <0.01 indicate significant increases in P2Y 2 R expression over control, as determined by t-test, and ‡ P <0.05 indicates a significant decrease in P2Y 2 R expression at 48 weeks of age, as compared to 25 weeks of age, as determined by ANOVA of 10-week-old Tg + P2Y 2 R +/− mice did not show any lesions in the major organs (i.e., brain, ileum/cecum/large intestine, kidneys, liver, lung, salivary glands, spleen, stomach and thymus) and bacterial/viral serology data were negative for Mycoplasma pulmonis , ectromelia, epizootic diarrhea of infant mice virus (EDIM), lymphocytic choriomeningitis virus (LCMV), mouse hepatitis virus (MHV), mouse norovirus (MNV), mouse parvovirus (MPV), mouse minute virus (MMV), pneumonia virus of mice (PVM), reovirus type 3 ( R E O 3 ) , S en d a i v i r u s , an d T h e i l er ' s m u r i n e encephalomyelitis virus (TMEV), suggesting that organ failure and infection were not causes of premature death. As anticipated, RT-PCR analysis demonstrated that the levels of P2Y 2 R mRNA expression in the brains of Tg + P2Y 2 R +/− mice were significantly decreased by~50 % (P < 0.01), as compared to Tg + mice (Fig. 2b) Previous characterization of the TgCRND8 mouse has described the initial appearance of Aβ plaques within the brain at~3 months of age [31] . To investigate Aβ plaque levels, 10-week-old TgCRND8 and Tg + P2Y 2 R +/− mouse brains were sectioned and stained with Congo Red (Fig. 3a-d) and then subjected to bright field microscopy (Fig. 3a, b) or polarized light microscopy where Aβ plaques were identified by their apple-green birefringence (Fig. 3c, d) . Alternatively, frozen brain sections from 10-week-old TgCRND8 and Tg + P2Y 2 R +/− mice were stained with an anti-β-amyloid antibody (Fig. 3e, f ) and plaques were visualized under fluorescence microscopy. Both methods of plaque visualization showed increased plaque load in Tg + P2Y 2 R +/− mouse brain (Fig. 3b, d, f) , as compared to age-matched TgCRND8 mouse brain (Fig. 3a, c, e) . A significant increase in Aβ plaque load (P <0.01) was observed in the occipital, parietal and frontal lobes of Tg + P2Y 2 R +/− mouse brain, as compared to age-matched TgCRND8 mouse brain (Fig. 3g) . There was also a significant increase in plaque size (P <0.01) for Tg + P2Y 2 R +/− vs. TgCRND8 mouse brains (Fig. 3h ). Previous reports with TgCRND8 mice have shown that levels of soluble Aβ 1-42 gradually increase from 4 to 8 weeks of age with accelerated accumulation beyond 10 weeks of age [31] . Accordingly, we investigated the levels of soluble Aβ 1-42 in 10-week-old Tg + P2Y 2 R +/− and TgCRND8 mouse brains using human Aβ 1-42 -specific ELISA. There were significant increases in levels of both soluble and total Aβ 1-42 (P <0.05) in the brains of Tg + P2Y 2 R +/− mice, as compared to agematched TgCRND8 mice (Fig. 4) . Taken together, these data suggest that the P2Y 2 R may play a role in the regulation of production or degradation of Aβ in TgCRND8 mouse brain. +/− and Tg + mouse brains at 10 weeks of age, RNA was isolated from brain samples and cDNA was prepared for RT-PCR analysis (b), as described in Methods. Data are presented as means ± SEM (n =6), where **P <0.01 indicates a significant decrease in P2Y 2 R mRNA expression, as compared to age-matched TgCRND8 mice substantial increase in the expression of APP and sAPPα in TgCRND8 mouse brain, as compared to Tg − controls, but APP and sAPPα expression levels were similar in Tg + P2Y 2 R +/− and TgCRND8 mouse brains (Fig. 5a ). Previously, we demonstrated that activation of P2Y 2 Rs stimulates α-secretase-dependent APP processing in neurons and astrocytoma cells, which generates non-neurotoxic sAPPα rather than neurotoxic Aβ [24, 36] . One possible explanation for increased Aβ levels in Tg + P2Y 2 R +/− mice (Figs. 3 and 4) could be decreased α-secretase activity. However, sAPPα expression was similar in the brains of TgCRND8 and Tg + P2Y 2 R +/− mice (Fig. 5a ). We also found that the α-secretases ADAM10 and ADAM17 (also known as TACE), members of the ADAM family of matrix metalloproteinases known to be the primary α-secretases responsible for processing of the APP holoprotein [37, 38] and the regulation of Aβ levels in the brain [39, 40] , were expressed at similar levels in Tg + P2Y 2 R +/− and TgCRND8 mouse brain (Fig. 5b) . In addition, BACE1, the primary β-secretase responsible for Aβ generation [41, 42] whose levels are altered in AD patients [43, 44] , is expressed at similar levels in Tg + P2Y 2 R +/− and TgCRND8 mouse brain (Fig. 5b) . It is now widely accepted that microglia in the brain can regulate degenerative or protective mechanisms depending on the conditions [45] . Previous studies from our laboratory have demonstrated that P2Y 2 R activation increases the migration of microglia and their uptake and degradation of Aβ [25] . Expression of the microglial cell marker CD11b has been shown to increase during microglial activation [46] , which enhances phagocytic activity [47] Mice harboring neurological deficits display an abnormal limbclasping reflex in which the limbs are flexed inwards rather than extended [48] . TgCRND8 and Tg + P2Y 2 R +/− mice were elevated by the tail and qualitatively observed for the presence of abnormal limb-clasping reflex. At 10 weeks of age, Tg + P2Y 2 R +/− mice displayed abnormal limb-clasping reflexes, whereas this abnormality was absent in age-matched TgCRND8 mice (Fig. 7a) . A further assessment of neurological status can be achieved by analyzing gait, a commonly used indication of possible locomotor dysfunction in mouse models of neurodegeneration, including Parkinson's disease, Huntington's disease, stroke and traumatic brain injury [49] [50] [51] . Gait analysis using a Noldus CatWalk system indicated that Tg + P2Y 2 R +/− as compared to age-matched TgCRND8 mice (n =7) exhibited a significant decrease (P <0.05) in swing speed (speed of the paw while not in contact with the walkway) and stride length (distance between successive paw placements) (Fig. 7b, c) . Additionally, the regularity index, a measure of interpaw coordination defined as the number of normal step sequence patterns relative to the number of paw placements, was significantly decreased (P <0.05) in Tg + P2Y 2 R +/− as compared to TgCRND8 mice (Fig. 7d) . These results support the hypothesis that the P2Y 2 R plays a neuroprotective function in the TgCRND8 mouse model of AD. ) mice were subjected to Western analysis, as described in Methods. (a) APP and sAPPα levels were determined using anti-APP antibody (clone 6E10) and anti-sAPPα antibody (clone 2B3), respectively. (b ) ADAM10, ADAM17 and BACE1 levels were determined using anti-ADAM10, anti-ADAM17 and anti-BACE1 antibodies, respectively. Blots are representative of results from n =6 mice for each genotype, and α-tubulin was used as a loading control Fig. 6 Heterozygous knockout of the P2Y 2 R in TgCRND8 mice leads to decreased expression of CD11b in the brain. Brain cell homogenates prepared from 10-week-old TgCRND8 and Tg + P2Y 2 R +/− mice, and Tg − P2Y 2 R +/− and Tg − control mice (n =6) were subjected to RT-PCR analysis using specific primers for the microglial cell marker CD11b. The fold increase in CD11b mRNA expression over age-matched controls is expressed as the mean ± SEM (n =6), where *P <0.05 indicates a significant decrease in CD11b mRNA expression, as compared to TgCRND8 mice
Discussion
We present evidence that the P2Y 2 R plays a neuroprotective role in the TgCRND8 mouse model of AD, since global heterozygous deletion of the P2Y 2 R increased soluble and total Aβ 1-42 levels and Aβ plaque deposition, decreased expression of the microglial cell marker CD11b, enhanced neurological deficits and accelerated mortality, as compared to TgCRND8 mice expressing a full complement of the P2Y 2 R. Another interesting observation is that after the initial upregulation of P2Y 2 R during the early stage disease pathology of TgCRND8 mice (10-25 weeks), the expression of P2Y 2 R decreases as the mice age and disease progresses (25-48 weeks) . Furthermore, we found that increased Aβ accumulation in the Tg + P2Y 2 R +/− mouse does not correlate with changes in levels of APP or the APP processing enzymes ADAM10, ADAM17 or BACE1 and, therefore, it seems likely that decreased microglial cell activation and/or recruitment due to P2Y 2 R deletion is a major factor in the inefficient Aβ clearance and the neurological deficits and shortened life span of Tg + P2Y 2 R +/− mice. These data support the hypothesis that P2Y 2 R provides neuroprotection in the TgCRND8 mouse model of AD and suggest a novel target for the treatment of neurodegenerative diseases.
Previous work has demonstrated that the P2Y 2 R is upregulated in cell and animal models of vascular, salivary gland and intestinal inflammation [22, 52, 53] . Upregulation of the P2Y 2 R has been shown to occur through the activation of the transcription factor NF-κB that is known to regulate inflammatory responses [53] . We found that the P2Y 2 R is upregulated in TgCRND8 mice within 10 weeks of age (Fig. 1) , a time point that correlates with the initial appearance of Aβ plaques (~10-12 weeks) [31] . P2Y 2 R expression levels remain elevated through 25 weeks of age, but return to levels similar to Tg − littermate controls by 48 weeks. These data suggest that P2Y 2 R-mediated neuroprotection is available early in disease progression, but is lost in the later stages of disease. Interestingly, studies have demonstrated decreased levels of P2Y 2 R expression in post-mortem parietal cortex samples from AD patients as compared to non-AD controls [30] , suggesting that loss of P2Y 2 R contributes to end-stage events in AD. However, whether P2Y 2 R expression is upregulated early in human AD to slow disease progression is not known. Since we have shown that P2Y 2 R expression is upregulated in rat primary cortical neurons by IL-1β [24] and by Aβ exposure in mouse primary microglia [25] , it seems likely that P2Y 2 Rmediated neuroprotection (e.g., microglia-dependent Aβ clearance) would be most pronounced with inflammation at early stages of AD-like disease progression in TgCRND8 mice. The formation of insoluble Aβ plaques and the presence of Tau-immunopositive dystrophic neurites within plaques are characteristic of AD [54] [55] [56] . TgCRND8 mice also develop amyloid plaques with associated dystrophic neurites; however, these neuritic plaques have been shown to be Tauimmunonegative [31, 57, 58] . Increased levels of neurotoxic soluble Aβ 1-42 accurately correlate with cognitive decline in AD patients [59, 60] . Our results demonstrate that soluble Aβ 1-42 levels are significantly increased with heterozygous P2Y 2 R deletion in the Tg + P2Y 2 R +/− mouse (Fig. 4) , in addition to increased Aβ plaque accumulation (Fig. 3) , suggesting that the P2Y 2 R in vivo can directly regulate the steady-state levels of neurotoxic forms of Aβ. Generation of the neurotoxic Aβ 1-42 peptide requires sequential processing of the APP holoprotein by β-and γ-secretases, whereas α-secretase activity is required to generate the non-amyloidogenic sAPPα fragment [42, 61, 62] . Studies have demonstrated that the α-secretases (i.e., ADAM10/17) compete with β-secretase (i.e., BACE1) for the processing of APP [63] [64] [65] . Therefore, modulating the activity of α-secretases can affect the production of neurotoxic forms of Aβ [39] . Previous in vitro studies in our laboratory indicate that P2Y 2 R activation in IL-1β-treated rat primary cortical neurons increases ADAM10/17-mediated APP processing by a PI3K-, PKC-and ERK1/2-dependent pathway [24] and by a Ca 2+ -dependent, but PKCindependent pathway in human astrocytoma cells [36] . The current study indicates that there are no differences in the levels of APP, sAPPα, and α-or β-secretases between TgCRND8 and Tg + P2Y 2 R +/− mice ( Fig. 5 ) and, therefore, a decrease in P2Y 2 R-dependent α-secretase or an increase in β-secretase expression upon heterozygous P2Y 2 R deletion does not contribute to the elevated levels of neurotoxic, soluble Aβ in Tg + P2Y 2 R +/− mice (Fig. 4) . Under neuroinflammatory conditions associated with AD, resident microglia become activated, proliferate and migrate towards and surround Aβ plaques [66] , and blood-derived macrophages infiltrate the brain [67, 68] . These activated microglia are thought to play a neuroprotective role through the phagocytosis [25, 69] and degradation [70] of neurotoxic forms of Aβ. The importance of microglia in controlling Aβ levels has been demonstrated in AD mouse models and AD patients where Aβ immunization has been shown to decrease plaque load and increase microglial cell accumulation [33, [71] [72] [73] . In the current study, we show that increased soluble and total Aβ levels and plaque deposition (Figs. 3 and 4) are associated with a decrease in the expression of the microglial cell marker CD11b in the brains of Tg + P2Y 2 R +/− mice, as compared to TgCRND8 mice (Fig. 6) . These results are consistent with the finding that increases in Aβ levels correlate with decreased CD11b + microglial cells in the brains of Tg2576 mice upon knockout of the CCR2 chemokine receptor [74] . Interestingly, it has previously been shown that prolonged IL-1β expression in the hippocampus of the APPswe/PS1dE9 mouse model of AD leads to a reduction in amyloid lesions that was attributed to increased activation of microglial cells [75] , consistent with a role for IL-1β-mediated P2Y 2 R upregulation in the TgCRND8 mouse model of AD.
An Arg-Gly-Asp (RGD) motif in the first extracellular loop of the P2Y 2 R has been shown to promote receptor interaction with α v β 3/5 integrins and the integrin-associated protein CD47 that mediate nucleotide-induced cytoskeletal rearrangements and cell migration by enabling the P2Y 2 R to access pools of G o and G 12 proteins associated with these integrins, thereby activating Rac1 and RhoA GTPases to regulate actin polymerization [76] [77] [78] . We recently reported that upregulation of P2Y 2 Rs in mouse primary microglial cells treated with oligomeric Aβ enhances Aβ uptake and degradation [25] , a neuroprotective mechanism that could slow disease progression in vivo. Furthermore, our data show that P2Y 2 R-mediated uptake of fibrillar Aβ 1-42 requires α v integrin, Src and Rac activities [25] , suggesting a direct role for P2Y 2 R/α v β 3/5 integrin interactions in Aβ uptake by microglia. Aβ interacts with a multi-component cell surface receptor complex, including the B-class scavenger receptor CD36, the α 6 β 1 integrin and CD47, to stimulate the phagocytic activity of microglial cells [79] [80] [81] . Since the P2Y 2 R and CD36 both interact with CD47 and its associated integrins, it is possible that the multi-protein complex that regulates the phagocytosis of Aβ by microglia includes the P2Y 2 R.
We observed an abnormal limb-clasping reflex in Tg + P2Y 2 R +/− mice ( Fig. 7) , which is a non-specific marker of neurological deficits that has been used to evaluate neurodegeneration in AD and Huntington's disease [82, 83] . Additionally, locomotor dysfunction such as reduced swing speed and stride length have been used to diagnose CNS damage in traumatic brain injury and stroke [48, 49] and in AD patients [84] . The neurological deficits seen with heterozygous P2Y 2 R deletion in TgCRND8 mice (Fig. 7) may be due to loss of an important regulatory mechanism involved in neurite extension, such as modulation of TrkA signaling and cofilin activity [85, 86] . Alternatively, neurological deficits seen in Tg + P2Y 2 R +/− mice may be secondary to increased accumulation of neurotoxic Aβ as a result of loss of P2Y 2 R-dependent Aβ clearance by microglia, since it has been shown that incomplete Aβ clearance is associated with early neuropathogenesis in AD [87] . The decrease in CD11b expression in Tg + P2Y 2 R +/− mice as compared to TgCRND8 mice could indicate a decrease in the number of microglia in the brain or inefficient microglial cell activation, as CD11b has been shown to be upregulated in activated microglia in the AD brain [46] . While further studies are needed to determine the cause of reduced CD11b expression, these results suggest an important role of the P2Y 2 R in enhancing microglia-mediated Aβ clearance. Future studies will help ascertain the molecular mechanism involved in P2Y 2 R deletion-dependent neurological deficits and validate P2Y 2 R as a target for therapeutic intervention in AD.
The data presented in this study provide strong in vivo evidence in support of the hypothesis that P2Y 2 R upregulation and subsequent activation in TgCRND8 mouse brain mediates neuroprotective responses. P2Y 2 R activation in endothelial cells also has been shown to regulate monocytic cell diapedesis [22, 88] , a process necessary for blood-derived macrophages to cross the blood-brain barrier. Studies using tissue-specific deletion of P2Y 2 Rs in microglia, neurons and endothelial cells may help elucidate the relevance of P2Y 2 Rs in each of these cell types to neuroprotection conferred by the P2Y 2 R in the TgCRND8 mouse model of AD.
